DK1396270T3 - Borsyresalte - Google Patents

Borsyresalte

Info

Publication number: DK1396270T3
Authority: DK; Denmark
Prior art keywords: boronic acid; formula; acid salts; species selected; boronic acids
Prior art date: 2002-09-09

Application number

DK03255629T

Other languages

English (en)

Inventor

David Jonathan Madge

Mark Dolman

Sophie Marie Tr Combe-Marzelle

John Joseph Deadman

Anthony James Kennedy

Sanjay Kumar Kakkar

Original Assignee

Trigen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-09

Filing date

2003-09-09

Publication date

2006-08-28

2002-09-09 Priority claimed from GB0220822A external-priority patent/GB0220822D0/en

2002-09-09 Priority claimed from GB0220764A external-priority patent/GB0220764D0/en

2003-04-04 Priority claimed from GB0307817A external-priority patent/GB0307817D0/en

2003-05-16 Priority claimed from GB0311237A external-priority patent/GB0311237D0/en

2003-07-04 Priority claimed from GB0315691A external-priority patent/GB0315691D0/en

2003-09-09 Application filed by Trigen Ltd filed Critical Trigen Ltd

2006-08-28 Application granted granted Critical

2006-08-28 Publication of DK1396270T3 publication Critical patent/DK1396270T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK03255629T 2002-09-09 2003-09-09 Borsyresalte DK1396270T3 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB0220822A GB0220822D0 (en)	2002-09-09	2002-09-09	Boropeptides
GB0220764A GB0220764D0 (en)	2002-09-09	2002-09-09	Boropeptides
GB0307817A GB0307817D0 (en)	2003-04-04	2003-04-04	Boronic acid compounds
GB0311237A GB0311237D0 (en)	2003-05-16	2003-05-16	Boronic acid compounds
GB0315691A GB0315691D0 (en)	2003-07-04	2003-07-04	Boropeptides
US48578603P	2003-07-08	2003-07-08

Publications (1)

Publication Number	Publication Date
DK1396270T3 true DK1396270T3 (da)	2006-08-28

Family

ID=31721886

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03255629T DK1396270T3 (da)	2002-09-09	2003-09-09	Borsyresalte
DK03255590T DK1400245T3 (da)	2002-09-09	2003-09-09	Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03255590T DK1400245T3 (da)	2002-09-09	2003-09-09	Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering

Country Status (19)

Country	Link
EP (8)	EP1396270B1 (da)
JP (3)	JP2006509034A (da)
KR (2)	KR20050057295A (da)
CN (2)	CN100447151C (da)
AT (3)	ATE325611T1 (da)
AU (3)	AU2003263343A1 (da)
BR (1)	BR0314450A (da)
CA (3)	CA2535788A1 (da)
CY (1)	CY1105381T1 (da)
DE (3)	DE60317039T2 (da)
DK (2)	DK1396270T3 (da)
ES (2)	ES2263924T3 (da)
IL (1)	IL167294A (da)
MX (2)	MXPA05002662A (da)
NZ (2)	NZ539334A (da)
PL (2)	PL376439A1 (da)
PT (1)	PT1396270E (da)
SI (2)	SI1396270T1 (da)
WO (3)	WO2004022070A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0405272D0 (en) *	2004-03-09	2004-04-21	Trigen Ltd	Compounds
GB0405267D0 (en) *	2004-03-09	2004-04-21	Trigen Ltd	Compounds
GB0405280D0 (en) *	2004-03-09	2004-04-21	Trigen Ltd	Compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006059082A1 (en) *	2004-11-30	2006-06-08	Trigen Limited	Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0515003D0 (en) *	2005-07-21	2005-08-31	Univ Aston	Medical devices and coatings therefor
US7261742B2 (en)	2005-10-13	2007-08-28	S.C. Johnson & Son, Inc.	Method of deodorizing a textile
JP2010536875A (ja) *	2007-08-21	2010-12-02	アルザ・コーポレーシヨン	ボロン酸化合物のリポソーム製剤
AU2008288917A1 (en) *	2007-08-21	2009-02-26	Alza Corporation	Liposome compositions for in vivo administration of boronic acid compounds
US8389232B2 (en) *	2008-05-13	2013-03-05	The Regents Of The University Of California	Fluorescence detection of poison oak oil
HRP20150592T4 (hr)	2008-06-17	2025-02-14	Millennium Pharmaceuticals, Inc	Organoborni esterski spojevi i njihove farmaceutske kompozicije
WO2010059244A2 (en) *	2008-11-21	2010-05-27	Iroko Pharmaceuticals, Llc	Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
WO2010096574A1 (en)	2009-02-20	2010-08-26	Lisanti Michael P	A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN101928329B (zh) *	2009-06-19	2013-07-17	北京大学	三肽硼酸(酯)类化合物、其制备方法和应用
US10085987B2 (en)	2012-01-27	2018-10-02	Thomas Jefferson University	MCT protein inhibitor-related prognostic and therapeutic methods
EP2986290A4 (en)	2013-04-19	2017-01-04	Thomas Jefferson University	Caveolin-1 related methods for treating glioblastoma with temozolomide
ES2761774T3 (es) *	2014-10-01	2020-05-21	Merck Patent Gmbh	Derivados del ácido borónico
WO2017222914A1 (en)	2016-06-21	2017-12-28	Inception 4, Inc.	Carbocyclic prolinamide derivatives
EP4257191A3 (en)	2016-06-21	2023-11-22	Orion Ophthalmology LLC	Heterocyclic prolinamide derivatives
CN109187155B (zh) *	2018-07-27	2021-08-13	临沂大学	一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) *	2019-08-23	2020-04-24	브릿지바이오테라퓨틱스(주)	팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
JP7758028B2 (ja) *	2021-03-05	2025-10-22	Ａｇｃ株式会社	化合物、化合物の製造方法及び表面処理剤の製造方法
CN113121666B (zh) *	2021-03-10	2023-09-12	厦门大学	抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) *	2021-10-29	2023-04-18	重庆第二师范学院	一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5856695A (ja)	1981-09-28	1983-04-04	Nitto Boseki Co Ltd	新規なトロンビン測定用基質
US4499082A (en)	1983-12-05	1985-02-12	E. I. Du Pont De Nemours And Company	α-Aminoboronic acid peptides
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
EP0315574A3 (de)	1987-11-05	1990-08-22	Hoechst Aktiengesellschaft	Renin-Inhibitoren
US5574014A (en)	1988-04-28	1996-11-12	Thrombosis Research Institute	Inhibitors of trypsin-like enzymes
IL90244A (en)	1988-05-11	1993-05-13	Du Pont Merck Pharma	Peptide-drug compositions, for buccal and nasal administration, containing :-aminoboronic acid derivatives
US5106948A (en)	1988-05-27	1992-04-21	Mao Foundation For Medical Education And Research	Cytotoxic boronic acid peptide analogs
GB9017694D0 (en)	1990-08-13	1990-09-26	Sandoz Ltd	Improvements in or relating to organic chemistry
US5288707A (en)	1990-08-13	1994-02-22	Sandoz Ltd.	Borolysine peptidomimetics
GB9024129D0 (en)	1990-11-06	1990-12-19	Thrombosis Research Trust	Inhibitors and substrates of thrombin
US5648338A (en)	1990-11-06	1997-07-15	Thrombosis Research Institute	Inhibitors and substrates of thrombin
CZ230593A3 (en)	1991-04-30	1994-04-13	Procter & Gamble	Liquid detergents with arylboric acid
GB9224702D0 (en)	1992-11-25	1993-01-13	Thrombosis Res Inst	Boronic ester synthesis
FR2701951B1 (fr) *	1993-02-24	1995-06-09	Adir	Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
SG52766A1 (en)	1993-03-03	1998-09-28	Sandoz Ltd	Organic compounds
US5384410A (en) *	1993-03-24	1995-01-24	The Du Pont Merck Pharmaceutical Company	Removal of boronic acid protecting groups by transesterification
US5563127A (en)	1993-03-24	1996-10-08	The Dupont Merck Pharmaceutical Company	Boronic acid and ester inhibitors of thrombin
AU6448794A (en) *	1993-03-24	1994-10-11	Du Pont Merck Pharmaceutical Company, The	Boronic acid and ester inhibitors of thrombin
US5658885A (en)	1993-04-27	1997-08-19	The Dupont Merck Pharmaceutical Company	Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL109319A0 (en)	1993-04-27	1994-07-31	Du Pont Merck Pharma	Amidino and guanidino substituted boronic acid compounds
SE9900043D0 (sv)	1999-01-11	1999-01-11	Astra Ab	New use
US5681978A (en) *	1993-07-07	1997-10-28	Washington State University Research Foundation	Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
IL111175A0 (en) *	1993-10-07	1994-12-29	Du Pont Merck Pharma	Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
IL111176A0 (en) *	1993-10-07	1994-12-29	Du Pont Merck Pharma	Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
AU7922794A (en) *	1993-10-07	1995-05-01	Du Pont Merck Pharmaceutical Company, The	Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
US5462964A (en) *	1993-10-20	1995-10-31	The Du Pont Merck Pharmaceutical Company	Dipeptide boronic acid inhibitors of trypsin-like enzymes
US5431842A (en)	1993-11-05	1995-07-11	The Procter & Gamble Company	Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en)	1994-01-26	1994-03-23	Sandoz Ltd	Organic compounds
FR2721611B1 (fr)	1994-06-22	1996-09-27	Adir	Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) *	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
ATE252894T1 (de)	1995-01-05	2003-11-15	Univ Michigan	Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9502985D0 (en)	1995-02-16	1995-04-05	Thrombosis Res Inst	Enzyme inhibitors
GB9515489D0 (en)	1995-07-28	1995-09-27	Sandoz Ltd	Organic compounds
GB9613718D0 (en) *	1996-06-29	1996-08-28	Thrombosis Res Inst	Thrombin inhibitors
GB9724786D0 (en) *	1997-11-25	1998-01-21	Danbiosyst Uk	Oral delivery system
WO2001002601A2 (en)	1999-07-07	2001-01-11	Du Pont Pharmaceuticals Company	Cell-based assay systems for examining hcv ns3 protease activity
SE9904483D0 (sv)	1999-12-08	1999-12-08	Astra Ab	New use
US6462021B1 (en)	2000-11-06	2002-10-08	Astrazeneca Ab	Use of low molecular weight thrombin inhibitor
PT3078667T (pt) *	2001-01-25	2018-12-28	The United States Of America Represented By The Sec Dep Of Health And Human Services	Formulação de compostos de ácido borónico
DE10133786A1 (de)	2001-07-16	2003-02-06	Boehringer Ingelheim Pharma	Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

2003
- 2003-09-09 AU AU2003263343A patent/AU2003263343A1/en not_active Abandoned
- 2003-09-09 DE DE60317039T patent/DE60317039T2/de not_active Expired - Lifetime
- 2003-09-09 EP EP03255629A patent/EP1396270B1/en not_active Expired - Lifetime
- 2003-09-09 WO PCT/GB2003/003883 patent/WO2004022070A1/en not_active Ceased
- 2003-09-09 CA CA002535788A patent/CA2535788A1/en not_active Abandoned
- 2003-09-09 AT AT03255629T patent/ATE325611T1/de not_active IP Right Cessation
- 2003-09-09 CA CA002535792A patent/CA2535792A1/en not_active Abandoned
- 2003-09-09 JP JP2004569793A patent/JP2006509034A/ja active Pending
- 2003-09-09 NZ NZ539334A patent/NZ539334A/en not_active IP Right Cessation
- 2003-09-09 KR KR1020057004077A patent/KR20050057295A/ko not_active Ceased
- 2003-09-09 KR KR1020057004076A patent/KR20050057294A/ko not_active Ceased
- 2003-09-09 PT PT03255629T patent/PT1396270E/pt unknown
- 2003-09-09 DK DK03255629T patent/DK1396270T3/da active
- 2003-09-09 SI SI200330344T patent/SI1396270T1/sl unknown
- 2003-09-09 AU AU2003263328A patent/AU2003263328A1/en not_active Abandoned
- 2003-09-09 ES ES03255629T patent/ES2263924T3/es not_active Expired - Lifetime
- 2003-09-09 CN CNB038213907A patent/CN100447151C/zh not_active Expired - Fee Related
- 2003-09-09 AT AT03255590T patent/ATE324899T1/de not_active IP Right Cessation
- 2003-09-09 DE DE60305113T patent/DE60305113T2/de not_active Expired - Lifetime
- 2003-09-09 CN CNB038214032A patent/CN100553639C/zh not_active Expired - Fee Related
- 2003-09-09 EP EP03255604A patent/EP1396269A1/en not_active Withdrawn
- 2003-09-09 EP EP04076510A patent/EP1466916B1/en not_active Expired - Lifetime
- 2003-09-09 CA CA002536010A patent/CA2536010A1/en not_active Abandoned
- 2003-09-09 WO PCT/GB2003/003897 patent/WO2004022072A1/en not_active Ceased
- 2003-09-09 BR BR0314450-0A patent/BR0314450A/pt not_active IP Right Cessation
- 2003-09-09 EP EP04076548A patent/EP1561466A3/en not_active Withdrawn
- 2003-09-09 MX MXPA05002662A patent/MXPA05002662A/es not_active Application Discontinuation
- 2003-09-09 EP EP06113409A patent/EP1695711A3/en not_active Withdrawn
- 2003-09-09 JP JP2004569795A patent/JP2006511593A/ja active Pending
- 2003-09-09 PL PL03376439A patent/PL376439A1/xx unknown
- 2003-09-09 ES ES03255590T patent/ES2264515T3/es not_active Expired - Lifetime
- 2003-09-09 NZ NZ539333A patent/NZ539333A/en unknown
- 2003-09-09 DE DE60304956T patent/DE60304956T2/de not_active Expired - Lifetime
- 2003-09-09 DK DK03255590T patent/DK1400245T3/da active
- 2003-09-09 SI SI200330345T patent/SI1400245T1/sl unknown
- 2003-09-09 PL PL376535A patent/PL376535A1/pl unknown
- 2003-09-09 MX MXPA05002661A patent/MXPA05002661A/es active IP Right Grant
- 2003-09-09 AT AT04076510T patent/ATE376551T1/de not_active IP Right Cessation
- 2003-09-09 EP EP06113648A patent/EP1695712A3/en not_active Withdrawn
- 2003-09-09 EP EP03255590A patent/EP1400245B1/en not_active Expired - Lifetime
- 2003-09-09 EP EP04076521A patent/EP1466917A1/en not_active Withdrawn
- 2003-09-09 JP JP2004569794A patent/JP2006503903A/ja active Pending
- 2003-09-09 AU AU2003263333A patent/AU2003263333A1/en not_active Abandoned
- 2003-09-09 WO PCT/GB2003/003887 patent/WO2004022071A1/en not_active Ceased
2005
- 2005-03-07 IL IL167294A patent/IL167294A/en not_active IP Right Cessation
2006
- 2006-07-03 CY CY20061100903T patent/CY1105381T1/el unknown

Also Published As

Publication number	Publication date
EP1466916B1 (en)	2007-10-24
ATE376551T1 (de)	2007-11-15
AU2003263343A1 (en)	2004-03-29
EP1396269A1 (en)	2004-03-10
DE60304956T2 (de)	2007-01-25
ATE325611T1 (de)	2006-06-15
CA2535792A1 (en)	2004-03-18
EP1400245B1 (en)	2006-05-03
CN1684693A (zh)	2005-10-19
EP1561466A2 (en)	2005-08-10
CN100447151C (zh)	2008-12-31
JP2006509034A (ja)	2006-03-16
WO2004022072A1 (en)	2004-03-18
EP1695711A3 (en)	2008-01-02
NZ539334A (en)	2007-11-30
DE60305113D1 (de)	2006-06-14
IL167294A (en)	2008-11-03
CY1105381T1 (el)	2010-07-28
EP1695711A2 (en)	2006-08-30
ES2263924T3 (es)	2006-12-16
PL376439A1 (en)	2005-12-27
SI1400245T1 (sl)	2006-10-31
DK1400245T3 (da)	2006-08-28
ATE324899T1 (de)	2006-06-15
AU2003263328A1 (en)	2004-03-29
AU2003263333A1 (en)	2004-03-29
MXPA05002662A (es)	2005-09-20
PT1396270E (pt)	2006-08-31
ES2264515T3 (es)	2007-01-01
CA2536010A1 (en)	2004-03-18
EP1400245A1 (en)	2004-03-24
SI1396270T1 (sl)	2006-10-31
EP1396270B1 (en)	2006-05-10
DE60305113T2 (de)	2006-12-07
JP2006503903A (ja)	2006-02-02
CA2535788A1 (en)	2004-03-18
DE60317039T2 (de)	2008-07-31
DE60317039D1 (de)	2007-12-06
PL376535A1 (pl)	2006-01-09
HK1063154A1 (en)	2004-12-17
WO2004022070A1 (en)	2004-03-18
NZ539333A (en)	2007-02-23
CN100553639C (zh)	2009-10-28
MXPA05002661A (es)	2005-08-19
EP1695712A2 (en)	2006-08-30
WO2004022071A1 (en)	2004-03-18
JP2006511593A (ja)	2006-04-06
EP1396270A1 (en)	2004-03-10
EP1466917A1 (en)	2004-10-13
EP1466916A1 (en)	2004-10-13
EP1695712A3 (en)	2008-01-09
EP1561466A3 (en)	2006-08-23
CN1681517A (zh)	2005-10-12
DE60304956D1 (de)	2006-06-08
KR20050057295A (ko)	2005-06-16
KR20050057294A (ko)	2005-06-16
BR0314450A (pt)	2005-07-26

Publication	Publication Date	Title
PL376439A1 (en)	2005-12-27	Multivalent metal salts of boronic acids for treating thrombosis
ATE248837T1 (de)	2003-09-15	Chinuclidin-acrylamide
NO945084D0 (no)	1994-12-29	Substituerte heterocykliske karboksylsyreamider, deres fremstilling og anvendelse som legemiddel
TR200302242T2 (tr)	2004-12-21	Protein kinaz önleyicileri olarak pirolopirimidinler
BR0212042A (pt)	2004-08-17	Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2004032909A3 (en)	2004-07-01	Stabilized pharmaceutical composition containing basic excipients
ATE103808T1 (de)	1994-04-15	N-(3,4-dimethoxycinnamoyl)-anthranilsaeure enthaltende arzneimittelzusammensetzungen.
SE9901573D0 (sv)	1999-05-03	New compounds
DE60035429D1 (de)	2007-08-16	Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE0102440D0 (sv)	2001-07-05	New compound
AU5879798A (en)	1998-09-08	Agents inhibiting progress of pterygium and postoperative recurrence of the same
HUP9802897A2 (hu)	2000-11-28	Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
WO2002064552A8 (en)	2002-12-12	1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
SE0102057D0 (sv)	2001-06-08	New Salts I
SE9901572D0 (sv)	1999-05-03	New compounds
SE0102058D0 (sv)	2001-06-08	New Salts II
WO2002006299A3 (en)	2002-06-06	Therapeutic uses for aminosterol compounds
CO5271692A1 (es)	2003-04-30	Agentes terapeuticos
ATE441653T1 (de)	2009-09-15	Phosphorenthaltende verbindugnen mit antithrombitische wirkung
ATE331509T1 (de)	2006-07-15	Zusammensetzung die paracetamol und niflumic säure enthält
DE60008430D1 (de)	2004-03-25	Verbindungen mit antithrombotischer wirkung